Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR4 | P51679 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 5/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.35 |
| ▸ | HPGD | P15428 | 3/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.34 |
| ▸ | UGT2B7 | P16662 | 1/20 | 0.33 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL354291 | 0.98 | CCR4 (0.39) | CCR4ALDH1A1CYP2A6ALOX12HSD17B10 | |
| SCHEMBL12386887 | 0.79 | TSHR (0.38) | CCR4ALDH1A1CYP2A6HSD17B10TSHR | |
| SCHEMBL354785 | 0.78 | TAAR1 (0.44) | CCR4ALDH1A1CYP2A6MAPTKDM4E | |
| SCHEMBL11197460 | 0.78 | ALDH1A1 (0.33) | CCR4ALDH1A1CYP2A6HSD17B10TSHR | |
| SCHEMBL2095658 | 0.78 | ALDH1A1 (0.33) | CCR4ALDH1A1CYP2A6HSD17B10TSHR | |
| SCHEMBL10605324 | 0.77 | HSD17B10 (0.38) | ALDH1A1CYP2A6HSD17B10TSHRTDP1 | |
| SCHEMBL11190782 | 0.77 | AKR1B1 (0.45) | ALDH1A1HSD17B10TDP1CYP1A2HPGD | |
| SCHEMBL8597805 | 0.74 | CYP3A4 (0.40) | CCR4ALDH1A1CYP3A4MAPTKDM4E | |
| SCHEMBL8186453 | 0.74 | CCR4 (0.33) | CCR4ALDH1A1CYP2A6 | |
| SCHEMBL11486005 | 0.74 | CYP2D6 (0.38) | ALDH1A1HSD17B10TSHRCYP1A2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357214-A1 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | PHENEX PHARMACEUTICALS AKTIENGESELLSCHAFT (DE) | 2023-11-09 | — | — | US | disclosed |
| EP-3735430-B1 | VINYLETHER-BASED POLYMER AS DIELECTRIC | CLAP CO LTD (KR) | 2023-09-13 | — | — | EP | disclosed |
| US-20230012655-A1 | URIDINE DIPHOSPHATE DERIVATIVES, PRODRUGS, COMPOSITIONS AND USES THEREOF | UNIV TUFTS (US) | 2023-01-19 | — | — | US | disclosed |
| US-20220119385-A1 | BICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2022-04-21 | — | — | US | disclosed |
| US-11124536-B2 | Uridine nucleoside derivatives, compositions and methods of use | TUFTS UNIVERSITY (US) | 2021-09-21 | — | — | US | disclosed |
| EP-3449925-B1 | URIDINE NUCLEOSIDE DERIVATIVES, COMPOSITIONS AND METHODS OF USE | UNIV TUFTS (US) | 2021-08-04 | — | — | EP | disclosed |
| US-20200399302-A1 | URIDINE NUCLEOSIDE DERIVATIVES, COMPOSITIONS AND METHODS OF USE | TUFTS UNIVERSITY | 2020-12-24 | — | — | US | disclosed |
| US-10632138-B2 | Uridine diphosphate derivatives, prodrugs, compositions and uses thereof | TUFTS UNIVERSITY (US) | 2020-04-28 | — | — | US | disclosed |
| US-20200048288-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-02-13 | — | — | US | disclosed |
| US-10544183-B2 | Uridine nucleoside derivatives, compositions and methods of use | TUFTS UNIVERSITY (US) | 2020-01-28 | — | — | US | disclosed |
| US-9913855-B2 | Uridine diphosphate derivatives, prodrugs, compositions and uses thereof | TUFTS UNIVERSITY (US) | 2018-03-13 | — | — | US | disclosed |
| US-9913855-B2 | Uridine diphosphate derivatives, prodrugs, compositions and uses thereof | TUFTS UNIVERSITY (US) | 2018-03-13 | — | — | US | disclosed |
| US-20170365791-A1 | HETEROAROMATIC COMPOUNDS FOR ORGANIC ELECTRONICS | BASF SE (DE) | 2017-12-21 | — | — | US | disclosed |
| US-9750760-B2 | Uridine diphosphate derivatives, prodrugs, compositions and methods for treating neurodegenerative disorders | TUFTS UNIVERSITY (US) | 2017-09-05 | — | — | US | disclosed |
| US-20160243148-A1 | URIDINE DIPHOSPHATE DERIVATIVES, PRODRUGS, COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS | TUFTS UNIVERSITY | 2016-08-25 | — | — | US | disclosed |
| US-20160075731-A1 | URIDINE NUCLEOSIDE DERIVATIVES, COMPOSITIONS AND METHODS OF USE | TUFTS UNIVERSITY | 2016-03-17 | — | — | US | disclosed |
| US-9163055-B2 | Methods for treating glaucoma using uridine diphosphate derivatives | TUFTS UNIVERSITY (US) | 2015-10-20 | — | — | US | disclosed |
| US-20150265647-A1 | URIDINE DIPHOSPHATE DERIVATIVES, PRODRUGS, COMPOSITIONS AND USES THEREOF | TUFTS UNIVERSITY | 2015-09-24 | — | — | US | disclosed |
| US-20140371167-A1 | URIDINE NUCLEOSIDE DERIVATIVES, COMPOSITIONS AND METHODS OF USE | TUFTS UNIVERSITY (US) | 2014-12-18 | — | — | US | disclosed |
| US-20140162972-A1 | URIDINE DIPHOSPHATE DERIVATIVES, PRODRUGS, COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS | TUFTS UNIVERSITY (US) | 2014-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11124536-B2 | Uridine nucleoside derivatives, compositions and methods of use | P2RY6, UPP1, UMPS | CCR4 2594/4885ALDH1A1 2982/4885CYP2A6 1265/4885 |
| US-20200399302-A1 | URIDINE NUCLEOSIDE DERIVATIVES, COMPOSITIONS AND METHODS OF USE | P2RY6, UPP1, UMPS | CCR4 2594/4885ALDH1A1 2982/4885CYP2A6 1265/4885 |
| US-20220119385-A1 | BICYCLIC COMPOUNDS | SLC10A1, PKD1, CYP11B2 | CCR4 1464/4885ALDH1A1 543/4885CYP2A6 153/4885 |
| US-20170365791-A1 | HETEROAROMATIC COMPOUNDS FOR ORGANIC ELECTRONICS | OR10J3, NR0B1, NR0B2 | CCR4 316/4885ALDH1A1 1283/4885CYP2A6 326/4885 |
| US-10544183-B2 | Uridine nucleoside derivatives, compositions and methods of use | P2RY6, UPP1, UMPS | CCR4 2594/4885ALDH1A1 2982/4885CYP2A6 1265/4885 |
| US-20140371167-A1 | URIDINE NUCLEOSIDE DERIVATIVES, COMPOSITIONS AND METHODS OF USE | P2RY6, UPP1, UMPS | CCR4 2594/4885ALDH1A1 2982/4885CYP2A6 1265/4885 |
| US-20160243148-A1 | URIDINE DIPHOSPHATE DERIVATIVES, PRODRUGS, COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS | P2RY6, UMPS, UPP1 | CCR4 2899/4885ALDH1A1 2040/4885CYP2A6 282/4885 |
| US-20230012655-A1 | URIDINE DIPHOSPHATE DERIVATIVES, PRODRUGS, COMPOSITIONS AND USES THEREOF | UMPS, UPP1, UGDH | CCR4 3358/4885ALDH1A1 1514/4885CYP2A6 680/4885 |
| US-20230357214-A1 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | NR1H2, NR1H3, NR1H4 | CCR4 1861/4885ALDH1A1 3993/4885CYP2A6 1184/4885 |
| US-20160075731-A1 | URIDINE NUCLEOSIDE DERIVATIVES, COMPOSITIONS AND METHODS OF USE | P2RY6, UPP1, UMPS | CCR4 2594/4885ALDH1A1 2982/4885CYP2A6 1265/4885 |
| US-20200048288-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | MAP3K6, PIK3CA, MAP3K20 | CCR4 4735/4885ALDH1A1 4677/4885CYP2A6 3293/4885 |
| US-10632138-B2 | Uridine diphosphate derivatives, prodrugs, compositions and uses thereof | UMPS, UPP1, UGDH | CCR4 3358/4885ALDH1A1 1514/4885CYP2A6 680/4885 |
| US-20140162972-A1 | URIDINE DIPHOSPHATE DERIVATIVES, PRODRUGS, COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS | P2RY6, UMPS, UPP1 | CCR4 2899/4885ALDH1A1 2040/4885CYP2A6 282/4885 |
| US-20150265647-A1 | URIDINE DIPHOSPHATE DERIVATIVES, PRODRUGS, COMPOSITIONS AND USES THEREOF | UMPS, UPP1, UGDH | CCR4 3358/4885ALDH1A1 1514/4885CYP2A6 680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.